Cosmo Pharmaceuticals (OTC:CMOPF) Trading Down 2.3% – Here’s What Happened

Shares of Cosmo Pharmaceuticals (OTC:CMOPF) dropped 2.3% during mid-day trading on Wednesday . The stock traded as low as C$140.01 and last traded at C$140.01. Approximately 1,244 shares changed hands during trading, an increase of 45% from the average daily volume of 857 shares. The stock had previously closed at C$143.31.

Cosmo Pharmaceuticals Trading Down 2.3%

The business has a fifty day simple moving average of C$117.10 and a two-hundred day simple moving average of C$92.12.

About Cosmo Pharmaceuticals

Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology, endoscopy, dermatology, and healthtech worldwide. The company offers Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Lumeblue (methylene blue MMX), a diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy; Uceris/Cortiment, an oral tablet formulation which delivers budesonide directly to the lumen of the colon; Aemcolo/Relafalk, a GI antibiotic with MMX® technology and is approved for the treatment of travellers' diarrhoea; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Eleview, a medical device, which enables the safer and faster removal of colonic lesions; and GI Genius, a system that uses artificial intelligence to detect colorectal polyps during colonoscopy.